Isis Pharmaceuticals'

Clinical Trials

Current Advances

Positive Phase 2 Data for ISIS-FXIRx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery Published in the New England Journal of Medicine

Learn More